Investor Relations

At CelLBxHealth plc, we are committed to building long-term shareholder relationships based on transparency, accountability and clear communication.

2025 was a year of transition for the Company. Following a strategic review, CelLBxHealth repositioned the business towards a commercially focused, partner-led and capital-efficient model designed to accelerate growth and strengthen long-term value creation.

The Company also strengthened its leadership team and Board, while implementing significant operational efficiencies to create a leaner and more focused organization.

Our strategy is centered on expanding adoption of our circulating tumor cell (CTC) platform through partnerships  with leading diagnostics companies, including QIAGEN, Roche Diagnostics, and Illumina, supporting broader commercial adoption across research and clinical markets.

The Board remains confident in the long-term potential of the Company’s technology and market opportunity. We believe strong corporate governance is fundamental to sustainable growth, and CelLBxHealth continues to apply the QCA Code 2023 as the foundation of its governance framework.